Extendicare (TSE:EXE – Get Free Report) has been assigned a C$11.00 target price by analysts at BMO Capital Markets in a note issued to investors on Thursday,BayStreet.CA reports. The firm currently has a “market perform” rating on the stock. BMO Capital Markets’ price target suggests a potential upside of 5.97% from the company’s current price.
Several other research firms have also commented on EXE. Royal Bank of Canada upped their price target on shares of Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a report on Thursday, November 28th. TD Securities raised their target price on Extendicare from C$9.50 to C$10.50 and gave the stock a “hold” rating in a report on Thursday, November 14th.
Read Our Latest Research Report on Extendicare
Extendicare Stock Performance
Extendicare (TSE:EXE – Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported C$0.19 EPS for the quarter. Extendicare had a net margin of 4.28% and a return on equity of 60.00%. During the same quarter in the previous year, the business posted $0.13 earnings per share. Analysts anticipate that Extendicare will post 0.6134729 earnings per share for the current fiscal year.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
- Five stocks we like better than Extendicare
- 10 Best Airline Stocks to Buy
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- ASML: Strengths and Upside Remain Despite DeepSeek Worries
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Royal Caribbean Soars, But Smooth Sailing Isn’t Guaranteed
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.